InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (32 ops.)
Explore the complete record of transactions filed by Gallagher Cam, President. Insider active across 1 companies, notably Zentalis Pharmaceuticals, Inc.. Aggregated, 34 disclosures have been recorded. Total volume traded: €7.3m. The latest transaction was disclosed on 30 May 2022 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Declarations34 total
0111,072 shares0
Common Stock
SEC:0001725160-22-000116:0·
€199,1544,369 shares@ €45.58350.069% mcap2.7% of flow
Common Stock
SEC:0001725160-22-000067:0·
€173,3924,578 shares@ €37.8750.060% mcap2.4% of flow
Common Stock
SEC:0001725160-22-000061:0·
€391,3369,477 shares@ €41.29320.14% mcap5.3% of flow
Common Stock
SEC:0001725160-22-000057:0·
€147,8753,264 shares@ €45.30490.051% mcap2.0% of flow
Common Stock
SEC:0001725160-22-000038:0·
08,203 shares0
Common Stock
SEC:0001725160-22-000032:0·
€105,4962,290 shares@ €46.06810.037% mcap3.3% of flow
Common Stock
SEC:0001725160-22-000019·
€105,4962,290 shares@ €46.06810.037% mcap1.4% of flow
Common Stock
SEC:0001725160-22-000019:0·
€185,7053,434 shares@ €54.07840.064% mcap5.8% of flow
Common Stock
SEC:0001725160-22-000011·
€185,7053,434 shares@ €54.07840.064% mcap2.5% of flow
Common Stock
SEC:0001725160-22-000011:0·
€155,4532,397 shares@ €64.85320.054% mcap4.8% of flow
Common Stock
SEC:0001725160-22-000004·
€155,4532,397 shares@ €64.85320.054% mcap2.1% of flow
Common Stock
SEC:0001725160-22-000004:0·
€189,9563,001 shares@ €63.29760.066% mcap5.9% of flow
Common Stock
SEC:0001725160-21-000240·
€189,9563,001 shares@ €63.29760.066% mcap2.6% of flow
Common Stock
SEC:0001725160-21-000240:0·
€630,97110,000 shares@ €63.09710.22% mcap19.7% of flow
Common Stock
SEC:0001725160-21-000235·
€630,97110,000 shares@ €63.09710.22% mcap8.6% of flow
Common Stock
SEC:0001725160-21-000235:0·
€433,6726,614 shares@ €65.56880.15% mcap13.5% of flow
Common Stock
SEC:0001725160-21-000224·
€433,6726,614 shares@ €65.56880.15% mcap5.9% of flow
Common Stock
SEC:0001725160-21-000224:0·
€178,0352,506 shares@ €71.04350.062% mcap5.5% of flow
Common Stock
SEC:0001725160-21-000213·
€178,0352,506 shares@ €71.04350.062% mcap2.4% of flow
Common Stock
SEC:0001725160-21-000213:0·
€106,2171,900 shares@ €55.90390.037% mcap3.3% of flow
Common Stock
SEC:0001725160-21-000201·
€106,2171,900 shares@ €55.90390.037% mcap1.4% of flow
Common Stock
SEC:0001725160-21-000201:0·
€354,3416,241 shares@ €56.77630.12% mcap11.0% of flow
Common Stock
SEC:0001725160-21-000191·
€354,3416,241 shares@ €56.77630.12% mcap4.8% of flow
Common Stock
SEC:0001725160-21-000191:0·
€159,1543,784 shares@ €42.05980.055% mcap5.0% of flow
Common Stock
SEC:0001725160-21-000174·
25 of 34 declarations
About Gallagher Cam
Cam Gallagher is a life sciences executive and co-founder of Zentalis Pharmaceuticals, Inc., a U.S.-listed biopharmaceutical company on Nasdaq. At Zentalis, he has served on the Board of Directors since the company’s founding in December 2014, held executive leadership responsibilities, and was promoted to President in May 2022. In that role, he was tasked with leading corporate and business development initiatives, supporting the company’s strategic execution and helping advance its clinical and organizational growth. ([ir.zentalis.com](https://ir.zentalis.com/news-releases/news-release-details/zentalis-pharmaceuticals-promotes-cofounder-cam-gallagher?utm_source=openai)) Before joining Zentalis in a full-time management capacity, Gallagher served as Chief Business Officer at Immusoft Corporation, a preclinical gene therapy company. His earlier career includes leadership and board roles across a range of oncology and biotech companies, including VelosBio, Oncternal Therapeutics, Retrosense Therapeutics, Sorrento Therapeutics, Zavante, Verus Pharma, CV Therapeutics, and Dura Pharma. This background points to long-standing experience in corporate development, strategic transactions, operations, and company building within the biopharmaceutical sector. ([ir.zentalis.com](https://ir.zentalis.com/news-releases/news-release-details/zentalis-pharmaceuticals-promotes-cofounder-cam-gallagher?utm_source=openai)) Notable achievements in his career include helping build Zentalis as a clinical-stage oncology company focused on targeted therapies and supporting the company’s growth from its early founding phase. Public filings and company announcements indicate that he played a meaningful role in corporate strategy and the advancement of Zentalis’s clinical pipeline. He has also served on the boards of multiple life sciences companies, underscoring his experience in governance and value creation in high-growth biotech environments. Gallagher holds an MBA from the University of San Diego and a BS in Business Administration from Ohio University. ([ir.zentalis.com](https://ir.zentalis.com/news-releases/news-release-details/zentalis-pharmaceuticals-promotes-cofounder-cam-gallagher?utm_source=openai))
